SXL
LCTX icon

Summit X LLC’s Lineage Cell Therapeutics LCTX Stock Holding History

Summit X LLC’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,925
Closed -$12.9K – 196
2023
Q3 		$12.9K Sell
10,925
-4,000
-27% -$5.44K ﹤0.01% 180
2023
Q2 		$21K Sell
14,925
-7,000
-32% -$9.67K 0.01% 269
2023
Q1 		$32.9K Sell
21,925
-8,000
-27% -$11.2K 0.01% 259
2022
Q4 		$47.3K Buy
29,925
+5,000
+20% +$6.3K 0.01% 236
2022
Q3 		$29K Sell
24,925
-5,000
-17% -$7.34K 0.01% 241
2022
Q2 		$48K Sell
29,925
-1,000
-3% -$1.32K 0.01% 237
2022
Q1 		$48K Sell
30,925
-1,000
-3% -$1.55K 0.01% 248
2021
Q4 		$78K Buy
31,925
+3,000
+10% +$7.02K 0.02% 252
2021
Q3 		$72K Sell
28,925
-75
-0.3% -$192 0.02% 253
2021
Q2 		$82K Sell
29,000
-3,000
-9% -$7.76K 0.02% 257
2021
Q1 		$75K Buy
32,000
+1,000
+3% +$2.4K 0.02% 255
2020
Q4 		$55K Buy
+31,000
New +$43.4K 0.02% 241
2020
Q2 		$25K Sell
29,000
-1,700
-6% -$1.5K 0.01% 202
2020
Q1 		$25K Buy
30,700
+9,500
+45% +$9.46K 0.01% 185
2019
Q4 		$19K Buy
21,200
+3,000
+16% +$2.5K 0.01% 229
2019
Q3 		$18K Hold
18,200
– – 0.01% 226
2019
Q2 		$21K Sell
18,200
-300
-2% -$346 0.01% 230
2019
Q1 		$25K Sell
18,500
-1,500
-8% -$1.87K 0.01% 232
2018
Q4 		$19K Buy
20,000
+569
+3% +$872 0.01% 200
2018
Q3 		$40K Buy
19,431
+5,715
+42% +$12K 0.02% 219
2018
Q2 		$24K Buy
13,716
+571
+4% +$1.15K 0.01% 205
2018
Q1 		$30K Buy
+13,145
New +$30.8K 0.02% 180
2017
Q3 		– Sell
-14,630
Closed -$41K – 188
2017
Q2 		$41K Buy
+14,630
New +$40.9K 0.03% 178

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Summit X LLC's LCTX Position: Q4 2023 in Review

Summit X LLC sold out of Lineage Cell Therapeutics (LCTX) in Q4 2023, closing a stake of 10,925 shares — an estimated $12.9K sold.

Summit X LLC first reported a position in LCTX in Q2 2017 and held it in 23 quarters. The position peaked at $82K in Q2 2021. 115 funds tracked by Wall St. Rank hold LCTX as of Q4 2023.

  • Summit X LLC reported no remaining Lineage Cell Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Summit X LLC sold 10,925 Lineage Cell Therapeutics shares in Q4 2023, an estimated $12.9K.
  • Summit X LLC first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 23 quarters.
  • Summit X LLC's Lineage Cell Therapeutics position peaked at $82K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2023.

Based on Summit X LLC's 13F filing for Q4 2023, filed 8 Feb 2024.